“Drug Repurposing of Loratadine as a DNMT1 Inhibitor: Comparative Evaluation with Cisplatin in Patient-Derived Oral Squamous Cell Carcinoma Cells”, Precis. Med. Com., vol. 4, no. 2, pp. 125–137, Dec. 2024, doi: 10.55627/pmc.004.02.1083.